Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Recapitulating the growth of the human heart to mature cardioids

Project description

A physiologically accurate heart model

To understand heart disease and develop new therapies, researchers need accurate cardiac models. Animal models do not faithfully recapitulate the physiology of the human heart, while stem cell-derived models remain too immature for testing drugs. The ERC-funded CardioGROWTH project aims to address this by developing a human organoid that reproduces key stages of heart development such as myocardial compaction, vascularisation and maturation. Researchers will combine advanced imaging and molecular profiling to deliver a physiologically accurate model of the human heart. This model could be used for disease prediction and drug discovery and for testing regenerative treatments.

Objective

Cardiovascular disease (CVD) is the leading global cause of death. Yet, breakthroughs in cardiac therapies are limited due to the poor predictive power of current models. While the animals fail to accurately replicate human heart physiology, the human pluripotent stem cell-derived models remain underdeveloped and immature for reliable disease modeling and therapy development. To address these challenges, we propose to further develop our cardiac organoid (“cardioid”) model and recapitulate the key stages of heart growth, including trabeculation, compaction, vascularization, and postnatal hypertrophy, resulting in physiological-like maturation. We hypothesize that these processes lead synergistically to postnatal heart maturation. Guided by developmental principles, we will combine signaling, metabolic, and genetic manipulations, as well as quantitative morphometric, functional, and molecular readouts on our high throughput cardioid platform. By leveraging advanced technologies (e.g. light sheet microscopy and single-cell proteomics), we will develop a physiologically relevant cardiac model that enables predictive cardiac disease modeling and drug discovery, paving the way for innovative therapies and regenerative medicine.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2024-ADG

See all projects funded under this call

Host institution

INSTITUT FUER MOLEKULARE BIOTECHNOLOGIE GMBH
Net EU contribution
€ 2 500 000,00
Address
DR BOHRGASSE 3
1030 Wien
Austria
Region
Ostösterreich Wien Wien
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
No data

Beneficiaries (1)